Compare Illumina, Inc. (ILMN) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Royal Bank of Canada — how do they compare? Illumina, Inc. trades at $190.8 (market cap $29.12B), while Royal Bank of Canada trades at $212.37 (market cap $292.32B). The key difference: Royal Bank of Canada is far larger — about 10× Illumina, Inc.'s market cap, and Royal Bank of Canada pays a 2.37% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | RY | |
|---|---|---|
Market Cap | $29.12B | $292.32B |
Sector | Health | Financials |
52-Week High | $205.10 | $217.87 |
52-Week Low | $91.00 | $134.80 |
Enterprise Value | $30.48B | — |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Royal Bank of Canada (RY) trades at $210.79, down slightly by 0.14% today. The stock shows a bullish technical trend with strong earnings performance, beating EPS estimates in three consecutive quarters. Revenue grew to $66.53 billion in 2025, with a net income margin of 31.85%. Analyst sentiment is mixed with a Buy consensus of 43% but a majority Hold rating. Recent insider selling and a dividend announcement highlight corporate activity.
RY presents a stable investment with solid profitability and dividend yield, but faces risks from high valuation multiples and macroeconomic sensitivity. Upside is supported by earnings growth and institutional holdings, while insider sales and debt levels warrant caution. The stock remains a core holding for dividend-focused portfolios amid moderate growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
